Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3228836 plus PegIFN in chronic hepatitis B on stable NA therapy
CTR20210891Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bepirovirsen, interferon alfa in Chronic Hepatitis B (CHB), sponsored by GSK. Started Apr 2021; status: completed.
02
Drugs
bepirovirseninterferon alfa
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20210891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210891.